Cycl-Arenicin-1

General Information


DRACP ID  DRACP00872

Peptide Name   Cycl-Arenicin-1

Sequence  RWCVYAYVRVRGVLVRYRRCW

Sequence Length  21

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
K562 Blast phase chronic myelogenous leukemia, BCR-ABL11 positive; Chronic myeloid leukemia Leukemia IC50=16.2 µM MTT assay 24h 1

Hemolytic Activity  Human erythrocytes: 15% Hemolysis=14 µM; 50% Hemolysis=65.5 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00872

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys3<--->Cys20; NCB: Arg1<--->Trp21

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C127H195N41O25S2

Absent amino acids  DEFHIKMNPQST

Common amino acids  R

Mass  311723

Pl  11.15

Basic residues  6

Acidic residues  0

Hydrophobic residues  9

Net charge  6

Boman Index  -5485

Hydrophobicity  -7.14

Aliphatic Index  92.38

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  15595

Absorbance 280nm  779.75

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 31234579

Title  Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization

Doi 10.3390/md17060376

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.